Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
The newly approved treatment, SKINVIVE by JUVÉDERM, is now the first and only hyaluronic acid injectable cleared specifically for improving neck appearance
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
With standout ADC and t-cell engager response data across hard-to-treat cancers
After Phase 3 results show major hair regrowth gains
The submission is backed by positive results from the Phase 3 AFFIRM study
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
